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INTRODUCTION
Patients with schizophrenia have a reduced life expectancy 
for several reasons, including increased incidence of accidents, 
cardiovascular disease (CVD), and infectious disease.1 In par-
ticular, CVD is one of the most important causes of mortality 
and is responsible for about 45% of the excess mortality of 
schizophrenia.2 Patients with schizophrenia show 2−3 times 
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ObjectiveaaWe designed a nationwide study with limited exclusion criteria to investigate the prevalence of metabolic syndrome (MetS) 
in Korea and its relationship with antipsychotic medications.
MethodsaaThis multicenter, cross-sectional, and observational study included patients diagnosed with schizophrenia or schizoaffective 
disorder. Sixteen hospitals enrolled 845 patients aged 18 to 65 years prescribed any antipsychotic medication between August 2011 and 
August 2013. MetS was diagnosed using the criteria of the modified Adult Treatment Panel III of the National Cholesterol Education 
Program with the Korean abdominal obesity definition (waist circumference ≥85 cm in women, ≥90 cm in men).
ResultsaaThe prevalence of MetS in all patients was 36.5% and was significantly higher in men than women (men, 40.8%; women, 
32.2%) and was significantly correlated with age [odds ratio (OR) 1.02] and duration of illness (OR 1.03). The prevalence of MetS across 
antipsychotic drugs in the major monotherapy group was as follows: 18.8% for quetiapine, 22.0% for aripiprazole, 33.3% for both amis-
ulpride and paliperidone, 34.0% for olanzapine, 35% for risperidone, 39.4% for haloperidol, and 44.7% for clozapine.
ConclusionaaThe prevalence of MetS is very high in patients with schizophrenia or schizoaffective disorder. Screening and monitoring 
of MetS is also strongly recommended. Psychiatry Investig 2017;14(1):44-50
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higher risk of CVD than healthy controls.1
Many factors, including poor diet, tobacco smoking, weight 
gain, and low physical exercise, affect CVD development in 
patients with schizophrenia.3-5 Recently, several medications, 
especially antipsychotics, have been identified as having a neg-
ative impact on the development of CVD.6,7 Several compre-
hensive reviews concluded that atypical antipsychotics signifi-
cantly increased the risk of certain CVDs, such as diabetes, 
compared with typical antipsychotics.6,8 Some studies also re-
ported a higher prevalence of diabetes and hypertension in pa-
tients with schizophrenia than healthy controls.3,9,10
This increased prevalence of CVD, diabetes, and hyperten-
sion and increased mortality may be partially due to Metabolic 
Syndrome (MetS). MetS includes five major components: 1) 
abdominal obesity; 2) hypertension; 3) increased fasting glu-
cose level; 4) hypertriglyceridemia; and 5) decreased high-
density lipoprotein (HDL).
The prevalence of MetS in patients with schizophrenia is 
2−4 times higher than in healthy individuals.8,11-13 The preva-
lence of MetS in patients with schizophrenia varies across 
studies: 35.4% in the Netherlands,14 32.3% in Belgium,15 40.9% 
in the United States CATIE study,12 22.8% in Thailand,16 27.5% 
in Japan,17 and 31.7% in Korea.13
The causes of this variety in the prevalence include the use 
of different definitions of MetS, such as that of the Adult Treat-
ment Panel III report (ATP III) of the National Cholesterol 
Education Program,12,14 the modified ATP III,13,15,17 and the In-
ternational Diabetes Federation (IDF).16 In addition, some 
studies of Asian patients used Asian or Korean criteria for ab-
dominal obesity. MetS is also partially dependent on the loca-
tion, lifestyle, and demographic characteristics of the patients, 
such as age, gender, and ethnicity.18-20 Patients in previous stud-
ies had very different demographic and clinical factors, such as 
mean age, male:female ratio, duration of illness, and prescribed 
antipsychotic medications. Finally, some studies investigated 
the prevalence of MetS in a limited number of patients or pa-
tients enrolled for other purposes and not for the actual study 
of this prevalence. Thus, there may have been a selection bias 
and the results from a limited number of patients or hospitals 
might not be generalizable.
To overcome these limitations, we designed a nationwide 
study with minimal exclusion criteria and from multiple psy-
chiatric units across the nation to investigate the prevalence of 
MetS in Korea and the relationship between psychiatric medi-
cation and MetS prevalence.
METHODS
This study was a multicenter, cross-sectional, and observa-
tional study of patients diagnosed with schizophrenia or 
schizoaffective disorder according to Diagnostic and Statistical 
Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) 
diagnostic criteria. Sixteen hospitals−3 mental hospitals and 
13 university-affiliated general hospitals−enrolled patients 
aged 18 to 65 years that had been prescribed any antipsychotic 
medication for the treatment of schizophrenia or schizoaffec-
tive disorder between August 2011 and August 2013. Of the 
892 patients who consented to participate in the study, we ex-
cluded 47 due to a lack of information, such as age, gender, 
blood pressure (BP), waist circumference, or blood laboratory 
results. Written informed consent was obtained from all pa-
tients and this study was approved by the Institutional Review 
Board of each hospital.
Patient demographic data and histories were obtained from 
their medical records and by interview. We asked the patients 
if they had any conditions such as diabetes, dyslipidemia, or 
hypertension, or were overweight when they enrolled in this 
study. Based on the patients’ reports, we divided these subjects 
into “patients with no medical disease” and “patients with 
medical disease”. Waist circumference was measured at the 
umbilical level in a standing position and BP was measured us-
ing standard mercury sphygmomanometers or clinically ap-
proved automatic BP devices after a 5-minute rest. Plasma 
HDL cholesterol, triglycerides, and fasting blood glucose were 
also measured after at least 8-hour fast. MetS was diagnosed 
with the definitions of the modified ATP III for Korea (three 
or more of the following five criteria):21 waist circumference 
≥85 cm in women or ≥90 in men, fasting blood glucose ≥100 
mg/dL or specific treatment for hyperglycemia, serum triglyc-
eride ≥150 mg/dL or specific treatment for a lipid abnormality, 
HDL <40 mg/dL in men or <50 mg/dL in women or specific 
treatment for a lipid abnormality, and arterial BP (≥130/85) or 
specific treatment for hypertension.
We defined the index date of each patient as the date of 
blood sampling and the index period as the 12-month period 
before the index date. We collected information on the dosage 
and duration of antipsychotics prescribed during the index 
period. We defined the “monotherapy group” as those patients 
who took only one antipsychotic drug during the index peri-
od. In the monotherapy group, patients were defined as the 
“major monotherapy group” if they took one of the following 
antipsychotics: amisulpride, aripiprazole, clozapine, haloperi-
dol, olanzapine, paliperidone, quetiapine, and risperidone.
To investigate the relationship between antipsychotic medi-
cation and MetS, we compared the prevalence of MetS in the 
major monotherapy group according to the antipsychotic medi-
cations. In addition, to estimate the effect of the antipsychotic 
dose on the development of MetS in the major monotherapy 
group, the doses of the major antipsychotics were converted to 
the olanzapine equivalent dose. We defined the cumulative 
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equivalent dose as the sum of the equivalent doses of the ma-
jor antipsychotics prescribed to the patient during the index 
period. We then investigated the effect of the cumulative 
equivalent dose and mean equivalent dose on the develop-
ment of MetS in the major monotherapy group. Equivalent ra-
tios of antipsychotics to olanzapine 1 mg were as follows: 0.029 
mg for amisulpride, 0.67 mg for aripiprazole, 0.05 mg for clo-
zapine, 2 mg for haloperidol, 2.22 mg for paliperidone, 0.027 
mg for quetiapine, and 3.33 mg for risperidone.22
All statistical analyses were performed using STATA (ver. 
13; Stata Corp., TX, USA). Comparisons of the prevalence of 
MetS according to antipsychotic medications or gender were 
made with the chi-square test. Correlations between MetS and 
other clinical variables such as age and duration of illness were 
performed using logistic regression analysis. All statistical 
analyses used two-tailed test and p value <0.05 was considered 
to be statistically significant.
RESULTS
Demographic data and clinical characteristics 
The number of patients in the final analysis was 842. The 
demographic and clinical characteristics are presented in Table 
1. The mean patient age was 40.2±11.2 years (range 18−65) 
and the number of male patients was 417 (49.5%). There was 
no significant difference in age according to gender (men, 
39.5±10.7; women, 40.9±11.7, t=-1.85, p=0.065). The mean 
illness duration in all participants was 12.9±9.4 years (range 
0−44). About 26% patients (n=219) reported that they had one 
or more medical diseases related to MetS when they enrolled 
in this study (defined as the medical disease group).
Of the 842 enrolled patients, 27 did not take any antipsy-
chotics during the index period; 14 were drug-naïve patients 
and the other patients (n=13) took antipsychotics more than 1 
year before the index date. In addition, 376 patients (mono-
therapy group) took only one of 17 antipsychotic medications 
during the index period. The numbers of patients in the major 
monotherapy group by the antipsychotics were as follows: ris-
peridone (n=100), clozapine (n=46), olanzapine (n=46), ar-
ipiprazole (n=41), paliperidone (n=39), haloperidol (n=32), 
amisulpride (n=18), and quetiapine (n=16). The other patients 
(n=38) took one of nine antipsychotics (Figure 1, Table 1).
There were no significant differences in the cumulative and 
mean equivalent doses of antipsychotics in the major mono-
therapy group between men and women (cumulative equiva-
lent dose: 4426.9±3161.7 mg vs. 3042.1±3718.3 mg, t=1.03, 
p=0.31; mean equivalent dose: 15.0±8.6 mg vs. 13.6±9.4 mg, 
t=1.4, p=0.16) (Table 1).
Prevalence of MetS
The prevalence of MetS in all patients was 36.5% (n=307) 
and was significantly lower in female patients (women, 32.2%; 
men, 40.8%; OR 0.66, 95% CI 0.50−0.88; age-adjusted p<0.001) 
and significantly correlated with age (OR 1.02, 95% CI 
1.01−1.04; p<0.001) and duration of illness (OR 1.02, 95% CI 
1.01−1.04; p=0.002). The prevalence of each component of 
MetS ranged from 35% to 50% (hyperglycemia, 35.0%; hyper-
triglyceridemia, 38.0%; HTN, 38.1%; low HDL, 42.4%; ab-
dominal obesity, 49.5%). Abdominal obesity was the most 
common component for both sexes (men, 51.3%; women, 
47.8%). There were significant differences in the prevalence of 
hypertension (men, 44.4%; women, 32.0%; OR 0.56, 95% CI 
0.42−0.75; age-adjusted p<0.001) and hypertriglyceridemia 
(men, 43.9%; women, 32.2%; OR 0.59, 95% CI 0.45−0.78; age-
adjusted p=0.009) by sex (Table 2).
Although 176 (28.3%) of the 623 patients with no medical 
Table 1. Clinical and Demographic characteristics of participants with schizophrenia or schizoaffective disorder 
Total Male Female
p value
(male vs. female)
Number of participants 842 417 (49.5%) 425 (50.5%)
Age (years) 40.2±11.2 39.5±10.7 40.9±11.7 t=–1.85, p=0.065
Duration of illness (years) 12.9±9.4 13.3±9.5 12.4±9.3 t=1.37, p=0.17
Number of patients with no medical disease 623 307 (73.6%) 316 (74.4%) χ2=0.059, p=0.81
Number of antipsychotics χ2=0.16, p=0.93
0 (drug-naïve or -free group) 27 13 (3.1%) 14 (3.3%)
1 (monotherapy group) 376 189 (45.3%) 187 (44.0%)
2 or more (combination group) 439 215 (51.6%) 224 (52.7%)
Cumulative equivalent dose of major antipsychotics 
  in the major monotherapy group (mg)
4239.0±3444.9 
(N=338)
4426.9±3161.7 
(N=173)
4042.0±3718.3 
(N=165)
t=1.03, p=0.31
Mean equivalent dose of major antipsychotics 
  in the major monotherapy group (mg)
14.3±9.0
(N=338)
15.0±8.6 
(N=173)
13.6±9.4 
(N=165)
t=1.41, p=0.16
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disease were diagnosed with MetS, 131 (59.8%) of the 219 pa-
tients who reported they had one or more MetS-related medi-
cal diseases were diagnosed with MetS.
Relationship between antipsychotic medications 
and the prevalence of MetS
The prevalence of MetS was slightly different by the number 
of antipsychotic medications but it was not statistically signifi-
cant (df=2,839, F=0.2, p=0.762): 33.3% (drug-naïve or free 
group), 35.4% (monotherapy group), 37.6% (multiple medica-
tion group).
Because of the possibility of a different effect of the antipsy-
chotics on MetS, we used only data in the major monotherapy 
group to investigate the relationship between antipsychotics 
and MetS. In the major monotherapy group (n=338), the prev-
alence of MetS according to antipsychotic medications was as 
follows: 18.8% for quetiapine, 22.0% for aripiprazole, 33.3% for 
both amisulpride and paliperidone, 34.0% for olanzapine, 35% 
for risperidone, 39.4% for haloperidol, and 44.7% for clozapine 
(Figure 2). The difference of the prevalence of MetS between 
quetiapine group and aripiprazole group was not significant 
(χ2=0.07, p=0.790). The prevalence of MetS strongly increased 
with an increase in the cumulative equivalent dose of the seven 
atypical antipsychotics in the major monotherapy group (OR 
1.00012, 95% CI 1.000032−1.000204, age- and sex-adjusted 
p=0.007). However, one typical antipsychotic drug (haloperi-
dol) did not show this significant correlation (OR 0.99989, 
95% CI 0.99975−1.00004, age- and sex-adjusted p=0.16).
There were no significant correlations found between the 
development of MetS and the mean equivalent dose of both 
the seven atypical antipsychotics (OR 1.03, 95% CI 1.00−1.06, 
age- and sex-adjusted p=0.069) and the one typical antipsy-
chotic drug (OR 0.95, 95% CI 0.90−1.01, age- and sex-adjusted 
p=0.083).
DISCUSSION
Our present study showed an overall prevalence of MetS in 
patients with schizophrenia or schizoaffective disorder of 
36.5%, with a higher prevalence in male patients (40.8% vs. 
32.2%). In addition, we found that the prevalence of MetS in-
creased significantly with an increase in patient age and dura-
tion of illness. When we analyzed the relationship between 
antipsychotics and MetS in patients prescribed major antipsy-
chotics in the monotherapy group, the prevalence of MetS was 
lowest with quetiapine (18.8%) and aripiprazole (22.0%) and 
Figure 1. Categorization of participants 
according to antipsychotic regimen dur-
ing the index period. 
Drug naive or drug free group (N=27)  
(no antipsychotic medication during the index period)
∙ Drug naive (N=14)
∙ Drug free (N= 13)
Monotherapy group (N=376)
(one antipsychotic medication during the index period)
∙  Major monotherapy group (N=338): amisulpride,  
aripiprazole, clozapine, haloperidol, olanzapine,  
paliperidone, quetiapine, risperidone
∙ Other monotherpay group (N=38)
Multiple usage of antipsychotic medications (N=439)
(two or more antipsychotic medications during the index period)
∙ Combination or switching group
Total patients 
(N=842)
Table 2. Prevalence of metabolic syndrome in patients with schizophrenia or schizoaffective disorder (N=842)
Total Male Female Odds ratio: female/male (95% CI)*
Metabolic syndrome 308 (36.5%) 171 (40.8%) 137 (32.2%) 0.66 (0.50–0.88)‡
Hyperglycemia 295 (35.0%) 145 (34.7%) 150 (35.3%) 1.00 (0.75–1.33)
Abdominal obesity 417 (49.5%) 214 (51.3%) 203 (47.8%) 0.85 (0.65–1.12)
Hypertension 321 (38.1%) 185 (44.4%) 136 (32.0%) 0.56 (0.42–0.75)‡
Hypertriglyceridemia 320 (38.0%) 183 (43.9%) 137 (32.2%) 0.59 (0.45–0.78)†
Low HDL 357 (42.4%) 170 (40.8%) 187 (44.0%) 1.12 (0.85–1.47)
*age-adjusted logistic regression, †p=0.009, ‡p<0.001. HDL: high-density lipoprotein
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highest with haloperidol (37.5%) and clozapine (45.7%). A sig-
nificant correlation between the cumulative 1-year dose and the 
development of MetS was found in patients prescribed one of 
the seven atypical major antipsychotics, not in patients pre-
scribed a typical antipsychotic drug.
The overall prevalence (36.5%) of MetS in our current study 
was higher than that reported in other studies with Asian in-
cluding reports from Thailand (22.8%), Taiwan (34.9% and 
23.8%), Japan (27.5%), and Korea (31.7%)13,16,17,23,24 and was 
more comparable to the rates reported from western coun-
tries,12 although most Asian studies used a lower criterion (≥80 
cm) of abdominal obesity than we did (≥85 cm). It is difficult 
to identify the reasons for this discrepancy because many fac-
tors affect the development of MetS, including medication, 
age, gender, definition of MetS, and lifestyle. However, one of 
the important causes may be the trend for an increase in obe-
sity and MetS during the past two decades in the Korean healthy 
population. A population-based study (n=183,159) has re-
ported that the prevalence of obesity in children and adoles-
cents in Korea increased from 5.8% in 1997 to 9.7% in 2005.25 
In addition, according to the population-based surveys per-
formed in 1998, 2001, 2005, and 2007 in Korea, the age-adjust-
ed prevalence of MetS increased significantly from 24.9% in 
1998 to 29.2% in 2001, 30.4% in 2005, and 31.3% in 2007.26 
Given this trend in healthy people, the results of our study, 
which enrolled patients from 2011 to 2013, can be more readi-
ly understood.
Our study found that the prevalence of MetS in male pa-
tients was eight percentage points higher than that of female 
patients. Other studies typically showed a higher prevalence of 
MetS in female patients.12,23,27 However, some studies of Asian 
patients using the modified ATP III criteria also showed a 
2.6−8% higher prevalence of MetS in men.17,23,24 This male pre-
ponderance of MetS observed in our study and other Asian 
reports can be explained by the use of different definitions of 
abdominal obesity. According to Tan et al.,28 the decreased 
waist circumference of the modified ATP III for the Asian 
healthy population increased the crude prevalence of MetS. 
This effect was more prominent in men (7.8% increase) than 
in women (4.5% increase). In addition, the use of a stricter 
definition of abdominal obesity for women (≥85 cm) in our 
current study than the Asian criterion (≥80 cm) could explain 
the higher prevalence of MetS in male patients.
Patients with schizophrenia or schizoaffective disorder have 
several risk factors for MetS. First, smoking is a well-known 
risk factor for this condition.29 Patients with schizophrenia 
have a higher frequency of smoking than healthy controls or 
nonpsychotic patients.1,30,31 Second, patients with schizophre-
nia tend to perform little exercise and eat more fat or sugar.5,32 
These unhealthy lifestyle behaviors can play a role in MetS de-
velopment in patients with schizophrenia. Third, many studies 
reported that some atypical antipsychotics, especially olanzap-
ine and clozapine, were associated with an increase in diabetes, 
weight gain, and MetS.33-36 According to a previous meta-anal-
ysis of head-to-head comparisons of the metabolic side effects 
of atypical antipsychotics,37 olanzapine produces more weight 
gain and a greater increase in cholesterol and glucose than 
other atypical antipsychotics. However, aripiprazole among 
atypical antipsychotics has shown a relatively lower risk of 
MetS than other antipsychotics.38-40 In line with these reports, 
the prevalence of MetS was highest in our clozapine group and 
the patients who had been prescribed aripiprazole had the sec-
ond lowest prevalence of MetS. Although the lowest preva-
lence was in the quetiapine group in our study, the size of this 
group was too small (n=16) to generalize its results.
We found a significant correlation between the cumulative 
equivalent dose and the increased prevalence of MetS in pa-
tients prescribed one of seven major atypical antipsychotics, 
Figure 2. Prevalence of metabolic syn-
drome and its five components across 
the major antipsychotics administered 
during the index period. risp: risperi-
done, quet: quetiapine, pali: paliperi-
done, olan: olanzapine, halo: haloperi-
dol, cloz: clozapine, arip: aripiprazole, 
ami: amisulpride, HDL: high-density li-
poprotein.
Low HDL
risp
quet
pali
olan
halo
cloz
arip
ami
Hypertriglyceridemia
Hypertension
Abdominal obesity
Hyperglycemia
Metabolic synd
0 10 20 30 40 50 60 70 
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and not in those prescribed a typical antipsychotic drug. How-
ever, this finding should be cautiously interpreted because we 
used only drug information during the 1 year before the index 
date for analysis and we did not obtain other information on 
risk factors such as lifestyle. Because MetS occurs insidiously 
and there are many risk factors of difficult quantification, it is 
difficult to identify the relationship between the antipsychotic 
dose and MetS. A literature review has reported a dose-depen-
dent relationship between the metabolic outcomes and serum 
concentrations only, not the daily administered dose of olan-
zapine and clozapine.41 Osborn et al.42 reported a positive cor-
relation between the antipsychotic dosage and cardiovascular 
mortality. Short-term studies have also reported increased 
weight gain, fasting glucose, and body fat during short-term 
atypical antipsychotic treatment.43,44
Some patients in our study took anti-depressant or mood 
stabilizers longer than 30 days during the index period (re-
spectively, 157 and 149 patients). These medications have vari-
able and inconsistent effects on MetS. Although most SSRI ex-
cept paroxetine have a neutral effect on the development of the 
side effects related to MetS, paroxetine, venlafaxine, and mir-
tazapine were associated with the increase of these side ef-
fects.45 Bupropion is related to the decreased weight.46 Our 
study showed no significant difference of the rate of MetS be-
tween the patients who took anti-depressant longer than 30 
days and the patients who did not (respectively, 31.8% vs. 
37.5%, df=1,840, F=1.77, p=0.183). Regarding to mood stabi-
lizers, topiramate was related to the decreased weight,47,48 while 
valproate, in contrast, was associated with increased weight 
gain.49 We could not find the significant effect of mood stabi-
lizers on MetS by comparison between the patients who took 
mood stabilizers longer than 30 days and the patients who did 
not (prevalence of Mets: 36.2% vs. 36.5%, respectively, df=1,840, 
F=0.00, p=0.951).
Our study had several limitations. First, although we tried to 
enroll patients who would be representative of the entire Kore-
an population with schizophrenia or schizoaffective disorder, 
there was the possibility of a selection bias due to the require-
ment for written informed consent. However, we estimated 
the prevalence of MetS from data on 842 patients, which is 
about 0.74% of the estimated 114,222 total number of schizo-
phrenia patients in Korea according to a 2011 nationwide epi-
demiological survey of mental disorders.50 Second, we cannot 
conclude that our findings on the effects of antipsychotic med-
ication on MetS indicate causality because we could not obtain 
complete information on the antipsychotic medication pre-
scribed to patients after onset and psychiatrists might have 
prescribed low-risk medications to patients at high risk of 
MetS development. Finally, information on prescribed medi-
cations for dyslipidemia, hypertension, diabetes, or obesity 
were not precisely gathered.
Notwithstanding these limitations, our current study has 
confirmed the high prevalence of MetS in patients with schizo-
phrenia or schizoaffective disorder and that this prevalence 
differs among antipsychotic medications. In addition, most 
patients diagnosed with MetS in our study cohort did not 
know they had it before participation. Therefore, patients who 
are prescribed antipsychotics should be routinely screened.
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